# US 11,304,990 B2 · Use of known compounds—intracellular infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,304,990 B2
- Document ID: US11304990B2
- Status: Granted
- Kind: B2
- Application number: 16/479,489
- Filed: 2018-01-19
- Published: 2019-12-12
- Granted: 2022-04-19
- Earliest claimed: 2017-01-20
- Assignees: Isr Immune System Regulation Holding AB (Publ)
- Applicants: Isr Immune System Regulation Holding AB (Publ)
- Inventors: Ola Winqvist; Emma Lindh; Robert Wallin; Matt Gregory; Steven Moss
- Web page: https://patentgrep.com/patent/US11304990B2

## CPC

- A61K 38/09: Luteinising hormone-releasing hormone [LHRH] {, i.e. Gonadotropin-releasing hormone [GnRH]}; Related peptides
- A61K 31/568: substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 31/10: Antimycotics
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/06: Antimalarials
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides a method of treating intracellular infections, in particular intracellular bacterial, fungal, and protozoal infections.

## Claims

### Claim 1

A method of treating or preventing an intracellular infection in a subject in need thereof, comprising administering to the subject an effective amount of a GnRH or a GnRH analog in combination with a sex hormone;
wherein the intracellular infection is selected from Mycobacterium tuberculosis, Mycobacteria causing atypical disease, Mycobacterium avium and M. intracellulare (also known as Mycobacterium avium-intracellulare complex, or MAC), M. kansasii, M. marinum, M. fortuitum, M. gordinae, Mycoplasma pneumoniae, M. genitalium, M. hominis, Ureaplasma urealyticum, U. parvum, Chlamydophila pneumoniae, Salmonella typhimurium, Toxoplasma gondii, Plasmodium falciparum, P. vivax, Trypanosoma cruzi, Cryptosporidium, Leishmania, Histoplasma capsulatum, Cryptococcus neoformans, and Encephalitozoon cuniculi.

### Claim 2 (depends on 1)

The method according to claim 1, comprising administering a GnRH analog, wherein the GnRH analog is selected from deslorelin, avorelin, leuprolide, triptorelin, buserelin, fertirelin, lutrelin, goserelin, histrelin, and nafarelin or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the subject is a female subject, and wherein the sex hormone is selected from oestradiol, a semi-synthetic ester of oestradiol, and a synthetic or semi-synthetic oestrogen analog.

### Claim 4 (depends on 3)

The method according to claim 3, comprising administering a GnRH analog, wherein the GnRH analog is selected from deslorelin, avorelin, leuprolide, triptorelin, buserelin, fertirelin, lutrelin, goserelin, histrelin, and nafarelin or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the subject is a male subject, and wherein the sex hormone is selected from testosterone and a testosterone analog.

### Claim 6 (depends on 5)

The method according to claim 5, comprising administering a GnRH analog, wherein the GnRH analog is selected from deslorelin, avorelin, leuprolide, triptorelin, buserelin, fertirelin, lutrelin, goserelin, histrelin, and nafarelin or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method according to claim 1, wherein administration of said sex hormone compensates for a castractive effect of said GnRH or GnRH analog.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the subject is treated with the GnRH or GnRH analog for a treatment period of one month or longer.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the subject is treated with the GnRH or GnRH analog for a treatment period of half a year or longer.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the subject is treated with the GnRH or GnRH analog for a treatment period of a year or longer.

### Claim 11 (depends on 8)

The method according to claim 8, comprising administering a GnRH analog, wherein the GnRH analog is selected from deslorelin, avorelin, leuprolide, triptorelin, buserelin, fertirelin, lutrelin, goserelin, histrelin, and nafarelin or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

The method according to claim 1, comprising oral, intramuscular, subcutaneous, sublingual, or nasal administration of the GnRH, GnRH analog, or sex hormone.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the subject is an adult female, and wherein the sex hormone is an oestrogen.

### Claim 14 (depends on 13)

The method of claim 13, further comprising administering a progestogen to the subject.

### Claim 15 (depends on 14)

The method according to claim 14, comprising administering a GnRH analog, wherein the GnRH analog is selected from deslorelin, avorelin, leuprolide, triptorelin, buserelin, fertirelin, lutrelin, goserelin, histrelin, and nafarelin or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 13)

The method according to claim 13, comprising administering a GnRH analog, wherein the GnRH analog is selected from deslorelin, avorelin, leuprolide, triptorelin, buserelin, fertirelin, lutrelin, goserelin, histrelin, and nafarelin or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the subject is a female subject.

### Claim 18 (depends on 17)

The method according to claim 17, comprising administering a GnRH analog, wherein the GnRH analog is selected from deslorelin, avorelin, leuprolide, triptorelin, buserelin, fertirelin, lutrelin, goserelin, histrelin, and nafarelin or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

The method according to claim 1, wherein the subject is a male subject.

### Claim 20 (depends on 19)

The method according to claim 19, comprising administering a GnRH analog, wherein the GnRH analog is selected from deslorelin, avorelin, leuprolide, triptorelin, buserelin, fertirelin, lutrelin, goserelin, histrelin, and nafarelin or a pharmaceutically acceptable salt thereof.